After three years of rehabilitation, 17-year-old brain tumor survivor gets his wish to walk through the doors of Fred Hutch
July 21, 2015
| By Megan Herndon / Fred Hutch News Services
Burke Tinsley could have gone to Disneyland or met his favorite celebrity, but when the Make-A-Wish Foundation came to him, the 17-year-old cancer survivor from Kentucky had other plans. He asked to come to Seattle to visit Microsoft Studios and the Fred Hutchinson Cancer Research Center.
Molecule that highlights cancer cells for surgery was pioneered by Fred Hutch’s Dr. Jim Olson, licensed by Blaze Bioscience Inc.
Sept. 25, 2014
| By JoNel Aleccia / Fred Hutch News Service
A new dye derived from scorpion venom that lights up cancer cells so surgeons can precisely target brain tumors will get a trial run in the U.S., Blaze Bioscience Inc. officials announced Thursday. FDA officials have approved an investigational new drug application for Tumor Paint BLZ-100, a molecule discovered and first developed by researchers at Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital and the University of Washington.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.